Complement inhibitor products are specialized therapies designed to block or inhibit the complement system, a part of the immune system that enhances the body’s ability to fight infections and remove damaged cells. Overactivation of the complement system can lead to tissue damage and contribute to diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and certain autoimmune disorders.

Types of Complement Inhibitors:

1. C5 Inhibitors: These target the C5 protein in the complement pathway to prevent inflammation and cell damage. Examples include Eculizumab and Ravulizumab, commonly used in PNH and aHUS Complement inhibitors.
2. C1 Inhibitors: These block the C1 protein, used in treating hereditary angioedema (HAE) to prevent swelling episodes.
3. Factor D Inhibitors: Block Factor D to reduce complement activation in diseases like geographic atrophy.
4. MASP-2 Inhibitors: Target MASP-2 in the lectin pathway, which plays a role in certain inflammatory and autoimmune conditions.

Uses:

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Hereditary Angioedema (HAE)
• Autoimmune and inflammatory diseases involving complement overactivation

Complement inhibitors reduce tissue damage, prevent complications, and improve quality of life for patients with complement-mediated disorders.